Skip to main content
MEDXF logo

Medexus Pharmaceuticals Inc. (MEDXF) Stock: Price, Forecast & Analyst Target

Medexus Pharmaceuticals Inc. (MEDXF) — price $3.90 (-6.47%), as of the Nov 19, 2026 trading session; market cap $123M.

Educational signal · not a buy or sell recommendation · How to read this

$3.90 −$0.27 (-6.47%) Market Cap $123M

Medexus Pharmaceuticals Inc. · MEDXF

Medexus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on oncology, hematology, rheumatology, auto-immune diseases, and allergy. Their portfolio includes products like Rasuvo, Metoject, and IXINITY, distributed in Canada and the United States.

Price as of Nov 19, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • CRDL · Cardiol Therapeutics Inc. · 49 /100
  • ORGO · Organogenesis Holdings Inc. · 28 /100
  • DERM · Journey Medical Corporation · 31 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$3.90
Change on the day-6.47%
Market capitalisation$123M—
Shares traded on the day13.7K

Price & events

Other perspectives

Council score for Medexus Pharmaceuticals (MEDXF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

4 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Neutral
ROE Negative
Gross Margin Moderate

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Medexus Pharmaceuticals (MEDXF), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Medexus Pharmaceuticals Inc. (MEDXF) is the company analyzed here. It employs 90 people. In Q1 FY2027 it reported revenue of $28M and net income of $530,185. The market values it at $123M.

2 · Latest results

What do the latest results show for Medexus Pharmaceuticals (MEDXF)?

Short answer · as of

The most recent reported quarter, Q1 FY2027, carried revenue of $28M. Against analyst estimates the company has EPS beat 5 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q1 FY2027$28M$530,185$0.02 (diluted)
Q4 FY2026$25M-$3M-$0.08 (diluted)
Q3 FY2026$25M$80,000$0.0025 (diluted)
Q2 FY2026$25M-$315,000-$0.01 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Medexus Pharmaceuticals (MEDXF)?

Short answer · as of

The distress and quality screens read Altman Z 1.47 · Piotroski F 5. Trailing ratios: ROE -4.7% · ROA -1.7% · current ratio 1.30 · earnings yield -2.0% · free-cash-flow yield -1.0%.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of 1.47 sits in the distress zone (elevated bankruptcy risk).
  • Negative return on equity (-4.7%) — the business is not currently generating profit on shareholder capital.
4 · What to check next?

What should you watch next at Medexus Pharmaceuticals (MEDXF)?

Short answer · as of

Current published price targets run low $7.00 · high $7.00 · consensus $7.00 · median $7.00 against a quoted price of $3.90 (as of Nov 19, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • Fewer than two score snapshots exist, so no score trend is shown.

Checked against the records this page reads, on the dates shown above.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$7.00 – $7.00
Consensus target
$7.00
Median target
$7.00

Consensus record · Captured .

Measured against a quoted price of $3.90 (as of Nov 19, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held MEDXF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported MEDXF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Common Questions About MEDXF

These answers are editorial: 1 of these 8 answers is drawn from the MEDXF research dossier (written Mar 16, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is MEDXF a good stock to buy?

Stock Expert AI does not rate MEDXF buy, sell or hold. Medexus Pharmaceuticals Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the MEDXF stock price today?

The last price recorded for Medexus Pharmaceuticals Inc. (MEDXF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the MEDXF price target?

The analyst consensus price target for Medexus Pharmaceuticals Inc. (MEDXF), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What do analysts say about MEDXF stock?

Investors should conduct their own due diligence and consider the company's financial performance, growth opportunities, and risk factors before making an investment decision. Key metrics to monitor include revenue growth, gross margin, profitability, and cash flow.

What are the key factors to evaluate for MEDXF?

Evaluate MEDXF on fundamentals, analyst consensus, and risk factors. To weigh it, read the analyst view under Analyst targets & estimates on this page. This can provide access to new technologies, expertise, or markets, accelerating its growth and reducing its financial risk. Not financial advice.

How frequently does MEDXF data refresh on this page?

MEDXF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven MEDXF's recent stock price performance?

Medexus Pharmaceuticals Inc. (MEDXF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized product portfolio targeting niche therapeutic areas. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider MEDXF overvalued or undervalued right now?

Medexus Pharmaceuticals Inc. (MEDXF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 16 figures on this page — 12 from Financial Modeling Prep (FMP) and 4 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.